| Studies should include biomarkers to identify potential sub-groups in order to support stratification in future clinical trials where possible. (D) |
| Clinical trials should ideally be multicentre, large-scale and include biomarkers where possible. This will ensure results are more generalizable and offer the opportunity to test whether a change in outcome measures is associated with change in biomarkers. (D) |
| Clinical trials should include younger children and individuals with ASD and intellectual disability to ensure generalizability to the whole population of people with ASD. (D) |
| Longer-term clinical trials lasting at least 6 months are required. (D) |
| There is a need to develop objective outcome measures that can reliably capture changes of core symptoms over time. (D) |
| Clinical trials should also include measures of quality of life of individuals with ASD. (D) |
| Large-scale, multicentre, RCT’s are needed to assess the effectiveness of social-communication interventions and applied behavioural analysis on a range of outcome measures. (D) |
| All interventional studies, including those investigating psychological and social interventions, should include measures of adverse effects (D) |
| Studies are needed to examine the effectiveness of behaviourally based daily life skills in adults with ASD. (D) |
| Studies are needed to examine the effectiveness of anti-victimisation CBT in adults with ASD (D) |
| Studies are needed to evaluate models of service provision using patient experience and functional outcomes in addition to standard clinical measures (D). |
